Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition

Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera and a radiopharmaceutical supply network.